Health Care · Pharmaceutical Preparations · Nasdaq · CIK 1062822 · FYE Dec 31 · Prices AT CLOSE 2026-07-30 (USD) — end-of-day, never a live or intraday quote
Last $2.34Day +0.86%Mkt cap $1.0B1Y +129.4%Off 52W high −12.7%Vol (1Y) 78.7%
Daily closing price, split-adjusted to the current basis; 3y shown of 5,294 bars on file. Sampled to 240 points — every point is a real close, none averaged. Price return, not total return (dividends excluded). Source marketstack.
| Short interest7.4% of sh out |
| Days to cover12.0d |
| 13F net flow (QoQ)+13.29% |
| Top-10 13F concentration90.7% |
| Next report (est.)2026-08-07 |
Short interest is FINRA semi-monthly, settlement 2026-07-15. 13F figures are quarterly filings, period 2026-Q1 — a lower bound on true ownership.
| Sales (TTM)$69.6M |
| Earnings (TTM)-$26.1M |
| ROE−39.7% |
| Net margin−101.1% |
| Debt / equity0.50× |
| Sales growth 3Y610.3% |
Screener basis: ratios from the latest reported fiscal year; Sales/Earnings are trailing twelve months in the reporting currency (USD). The P/E is a trailing FULL-YEAR P/E, not TTM. Missing lines are absent from the filings, never imputed.
| YTD+103.5% |
| 1Y+129.4% |
| 3Y+16.4% |
| 5Y−33.9% |
| 10Y−86.0% |
| Since incept. (ann.)−12.4% |
Total return through 2026-07-30 · series begins 2005-07-11. Only the windows this history actually covers are shown.
| Ann. volatility (1Y)78.7% |
| Ann. volatility (3Y)106.1% |
| Sharpe (1Y)1.39 |
| Sharpe (3Y)0.60 |
| Max drawdown (1Y)−34.1% |
| Max drawdown (3Y)−91.8% |
| Beta (3Y vs SPY)1.28 |
Daily simple returns, annualized; drawdown is peak-to-trough within the window. Beta is the OLS slope of monthly returns on SPY's over three years. Each figure is labeled by the window it was measured over — they are not comparable across windows.
| Manager | Shares | Value | % sh out | QoQ |
|---|---|---|---|---|
| Artal Group S.A. | 154.7M | $241M | 36.52% | +13.6% |
| FMR LLC | 45.1M | $70M | 10.63% | +19.1% |
| Siren, L.L.C. | 44.3M | $69M | 10.46% | +13.8% |
| Sessa Capital IM, L.P. | 17.9M | $28M | 4.23% | +497.1% |
| VANGUARD CAPITAL MANAGEMENT LLC | 9.5M | $15M | 2.25% | new |
| Point72 Asset Management, L.P. | 7.8M | $12M | 1.84% | +2651.4% |
| MILLENNIUM MANAGEMENT LLC | 4.9M | $8M | 1.17% | +2.6% |
| BlackRock, Inc. | 3.3M | $5M | 0.78% | +4.1% |
Reported 13F long positions as filed for 2026-Q1 (change vs 2025-Q4). 13F covers US-listed long equity only — the sum is a LOWER BOUND on institutional ownership, never a total.
| Period end | Reported | EPS | EPS YoY | Revenue | Rev YoY |
|---|---|---|---|---|---|
| 2026-03-31 | 2026-05-07 | $0.00 | — | $21.1M | +1572.1% |
| 2025-12-31 | 2026-03-05 | — | — | $5.5M | −79.3% |
| 2025-09-30 | 2025-11-06 | −$0.04 | — | $14.2M | +710.4% |
| 2025-06-30 | 2025-08-06 | $0.01 | — | $28.9M | +1652.6% |
EPS and revenue as reported in this filer's own XBRL — our extraction of the filings, not a vendor consensus feed, and never a beat/miss claim (we carry no estimates). YoY compares the same fiscal quarter a year earlier. Next report 2026-08-07 is ESTIMATED from filing cadence (median gap 92d) — not company-confirmed.
Reportable 100%
business segments · each slice's share of TAGGED segment revenue in the latest annual filing (XBRL, as filed). Untagged revenue is excluded from the denominator, so slices need not sum to consolidated sales.
